Euro-BioImaging is pleased to inform its community about the EP PerMed Fast Track Validation Programme, a funding opportunity designed to advance personalised medicine solutions towards clinical application and market readiness.
The Programme aims to overcome bottlenecks in the technology development by giving developers access to specialised validation centres, which provide the necessary infrastructure and expertise, for rigorous testing of new technology and concepts. This way, developers can ensure innovations meet the needs and expectations of end-users, including clinicians and patients.
Euro-BioImaging Nodes can play a pivotal role in this programme by partnering with applicants as validation centres. The Nodes can provide access to advanced imaging expertise, cutting-edge instruments, image data, and AI-driven tools supporting the validation of a wide range of personalised medicine innovations.
Key details:
Deadline for submissions: March 13, 2025, 16:00 CET
Funding available: Up to €80,000 per project
Programme duration: Six-month validation studies
For our Nodes, this is an opportunity to:
Respond to the needs of applicants to test and validate their Personalised Medicine solutions.
Co-apply with technology developers for this grant.
In selected projects, the applicants and their chosen validation centres, which could be Euro-BioImaging Node facilities, collaborate to create detailed project plans for the validation, ensuring the successful execution of their studies. At least 70% of the funding must be allocated to validation services.
This programme is open to start-ups and researchers from EU Member States or Horizon Europe-associated countries who have personalised medicine solutions at proof-of-concept stage or higher (TRL3+).
Don’t miss this chance to advance personalised medicine innovations with Euro-BioImaging’s expertise!
More news from Euro-BioImaging
September 2, 2026
Collaborate on the Development of PRISM: Standardized Metadata for Preclinical Imaging Datasets
The FoundingGIDE Preclinical Stream, in collaboration with Euro-BioImaging and international partners, has launched a new survey to support the development of PRISM (PReclinical…
Understanding therapy resistance in the tumour microenvironment
Therapies that target rapidly dividing cells have transformed the treatment of many cancers. Yet some promising therapies lose their effectiveness over time, allowing…